Premium
Safety and efficacy of transcatheter arterial chemoembolization with embospheres in treatment of hepatocellular carcinoma
Author(s) -
Hao Ming Zhi,
Lin Hai Lan,
Chen Qi Zhong,
Hu Yu Bin,
Chen Jian Bin,
Zheng Jian Xiong,
Zhou Dong,
Zhang Hui
Publication year - 2017
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12435
Subject(s) - lipiodol , medicine , hepatocellular carcinoma , transcatheter arterial chemoembolization , gastroenterology
Objective To investigate the safety and efficacy of transcatheter arterial chemoembolization ( TACE ) with embospheres for the treatment of unresectable hepatocellular carcinoma ( HCC ). Methods Patients with unresectable HCC who were treated with TACE followed by embosphere treatment (Embo‐ TACE ) or conventional TACE (c TACE ) between May 2010 and March 2014 were retrospectively included in this study. The Embo‐ TACE group received lipiodol and chemotherapeutic agent emulsion, followed by embospheres. The c TACE group received lipiodol and chemotherapeutic agent emulsion, followed by gelatin sponge pellets. Time to progression ( TTP ), overall survival ( OS ), overall response rate ( ORR ), and safety were compared between the two groups. Univariate and multivariate regression analyses of the factors affecting survival were conducted. Results The median TTP and OS in the Embo‐ TACE group were significantly longer than those in the c TACE group ( TPP : 7.0 months vs 5.4 months, P = 0.035; OS : 15 months vs 12 months, P = 0.032). Seven days after the first TACE treatment, alanine aminotransferase level was higher in the c TACE group than in the Embo‐ TACE group ( P = 0.015). The ORR did not significantly differ between the two groups ( P = 0.827). Additional therapy and local responses one month after the first TACE treatment were associated with OS . Conclusions Embo‐ TACE resulted in a significant improvement in TTP and OS for patients with unresectable HCC , compared with c TACE . Furthermore, Embo‐ TACE was better tolerated. Additional therapy and local responses one month after the first TACE were independent prognostic factors for OS .